Fleroxacin in the Treatment of Chancroid: An Open Study in Men Seropositive or Seronegative for the Human Immunodeficiency Virus Type 1
| Autor: | Elizabeth Agoki, William Malisa, Frank Plummer, Mark W. Tyndall, Jackoniah O. Ndinya-Achola, Pierre J. Plourde, Allan R. Ronald |
|---|---|
| Rok vydání: | 1993 |
| Předmět: |
medicine.medical_specialty
Fleroxacin biology business.industry Human immunodeficiency virus (HIV) virus diseases General Medicine urologic and male genital diseases medicine.disease biology.organism_classification medicine.disease_cause Chancroid female genital diseases and pregnancy complications Open study Internal medicine Existing Treatment Immunology medicine Haemophilus ducreyi business medicine.drug |
| Zdroj: | The American Journal of Medicine. 94:85S-88S |
| ISSN: | 0002-9343 |
| DOI: | 10.1016/s0002-9343(20)31144-x |
| Popis: | Fleroxacin was prescribed to treat both HIV-negative and HIV-positive men with proven chancroid in an open study. HIV-negative men were treated with a single 400-mg dose of fleroxacin, and HIV-positive men were treated with 400 mg daily for 5 days. Three of the 58 evaluable HIV-negative men were clinical and microbiologic failures, and two of the 22 evaluable HIV-positive men had persisting infection with Haemophilus ducreyi. Both regimens were well tolerated. Fleroxacin is an acceptable alternative to existing treatment regimens for chancroid in men. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|